IPF treatment, NXP002, Continues to Show Promise in Preclinical Studies
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Shape Therapeutics’ SHP-201, an experimental gene therapy for Parkinson’s disease, significantly reduced the levels of alpha-synuclein — a protein that plays a key role in the development of the neurodegenerative […] The post Parkinson’s gene therapy reduced alpha-synuclein in animal models appeared first on Parkinson's News Today.| Parkinson's News Today – The Web's Daily Resource for Parkinson's News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
